Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.

Heather A JaceneJohn CrandallYvette L KasamonRichard F AmbinderSteven PiantadosiDonna SerenaWayne KasecampRichard L Wahl

Published in: Molecular imaging and biology (2018)

Tositumomab and [131I]tositumomab was well-tolerated in patients with relapsed/refractory HL. Complete responses in LPHL support a therapeutic effect in this subtype. Early metabolic response assessments by [18F]DG-PET in HL after radioimmunotherapy appear to be more predictive than purely anatomic assessments.

Keyphrases

hodgkin lymphoma
pet imaging
computed tomography
acute lymphoblastic leukemia
acute myeloid leukemia
positron emission tomography
pet ct
multiple myeloma
diffuse large b cell lymphoma
replacement therapy